Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2005
05/26/2005WO2005046711A2 Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing
05/26/2005WO2005046704A1 Pharmaceutical product comprising tissue of the male vegetal reproductive system
05/26/2005WO2005046703A1 Use of strain of bacillus and byproducts thereof for inhibiting formation of blood vessels
05/26/2005WO2005046657A2 Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
05/26/2005WO2005046622A2 Custom vectors for treating and preventing pancreatic cancer
05/26/2005WO2005046621A2 Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
05/26/2005WO2005046614A2 System for treating and preventing breast cancer
05/26/2005WO2005046605A2 Compositions and methods of treating neurological diseases
05/26/2005WO2005046602A2 Vegf receptor antagonists
05/26/2005WO2005046597A2 Antibodies to cd44 glycoforms and uses thereof
05/26/2005WO2005046571A2 Lactoferrin as an adjuvant in cancer vaccines
05/26/2005WO2005046454A2 Methods of using gelsolin to treat or prevent bacterial sepsis
05/26/2005WO2005046449A2 Soluble tcr molecules and methods of use
05/26/2005WO2005025624A3 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases
05/26/2005WO2005021029A3 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
05/26/2005WO2005016246A3 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
05/26/2005WO2005010173A3 Keratinocyte culturing method and the use thereof
05/26/2005WO2005009363A3 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
05/26/2005WO2005009217A3 Diagnosis of pre-cancerous conditions using pcdgf agents
05/26/2005WO2005005954A3 Method, composition and kit for detecting phosphatidylserine (ps) on cell membranes
05/26/2005WO2005000209A3 An improved method and apparatus for dosing single and multi-agent therapy
05/26/2005WO2005000207A3 Pcdgf receptor antibodies and methods of use thereof
05/26/2005WO2004100987A3 Methods of using il-1 antagonists to treat neointimal hyperplasia
05/26/2005WO2004089299A3 Pulsatile transdermally administered antigens and adjuvants
05/26/2005WO2004083392A3 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
05/26/2005WO2004073604A3 Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
05/26/2005WO2004056312A3 Immunoglobulin variants and uses thereof
05/26/2005WO2003077841A3 Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
05/26/2005WO2002094854A8 P.aeruginosa mucoid exopolysaccharide specific binding peptides
05/26/2005WO2002093998A9 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
05/26/2005US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases
05/26/2005US20050113564 Chimeric receptors with 4-1BB stimulatory signaling domain
05/26/2005US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization
05/26/2005US20050113292 Protein mimetic for preventing HIV-1 entry to host cells of living subject through membrane fusion, wherein HIV-1 contains envelope glycoprotein gp41 that has plurality of peptides in pre-hairpin state, comprising at least two monomeric peptide strands and interstrand linker coupling peptide strands
05/26/2005US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis
05/26/2005US20050112751 Novel class of therapeutic protein based molecules
05/26/2005US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/26/2005US20050112721 Chimeric peptide immunogens
05/26/2005US20050112720 Soluble complexes of amylod beta peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
05/26/2005US20050112713 Methods of using Fab I and compounds modulating Fab I activity
05/26/2005US20050112690 Binding molecules for the extra-domain B of fibronectin for detection of arteriosclerotic plaque
05/26/2005US20050112675 Polypeptides gene expressed in fat tissue ; measurement concentration; using antibodies
05/26/2005US20050112660 Nucleotide sequence coding membrane protein; diagnosis, therapy of nervous system, psychological, brain disorders
05/26/2005US20050112618 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders
05/26/2005US20050112596 APRIL-A novel protein with growth effect
05/26/2005US20050112568 Dgks as modifiers of the p53 pathwha and methods of use
05/26/2005US20050112562 Inhibition of retroviral replication through modulation of the host cell ubiquitylation
05/26/2005US20050112559 Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (SARS)
05/26/2005US20050112556 Drug screening; endogenous human retrovirus; protein or peptide expressed by said retrovirus
05/26/2005US20050112554 An insertion/a deletion early-stage-specific molecular marker, a single nucleotide variation (SNV) early-stage-specific molecular marker; SARS-CoV (coronaviruses) strains obtained from the earliest infected patients in a SARS outbreak, uses of these data for diagnosis, drug/vaccine development
05/26/2005US20050112145 Dna vaccines coding antigen
05/26/2005US20050112144 Deactivated, cell-free; culture product using protease; harvesting; separation
05/26/2005US20050112143 Method of developing an immunogenic composition and HIV vaccine
05/26/2005US20050112142 Methods and compositions for treatment and prevention of HSV-2 infections and conditions
05/26/2005US20050112141 Compositions and methods for treatment of neoplastic disease
05/26/2005US20050112140 Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein
05/26/2005US20050112139 Immunogenic composition and method of developing a vaccine based on factor H binding sites
05/26/2005US20050112138 Glycosylation immunogens
05/26/2005US20050112137 Autoantigenic fragments, methods and assays
05/26/2005US20050112136 Human immunodeficiency virus vaccine
05/26/2005US20050112135 Ultrasound assisted transdermal vaccine delivery method and system
05/26/2005US20050112134 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
05/26/2005US20050112133 Chimera molecule containing protein and merozonite surface protein; induce immunologyresponse against antigens
05/26/2005US20050112132 Using autoimmune target antigen; multiple sclerosis
05/26/2005US20050112130 Enhanced B cell cytotoxicity of CDIM binding antibody
05/26/2005US20050112129 Compositions and methods for the diagnosis and treatment of tumors of glial origin
05/26/2005US20050112127 Treating with active material having heavy chain variable region of amino acid sequence 7 and light chain variable region of sequence 8; psoriasis, multiple sclerosis, Crohn's disease
05/26/2005US20050112126 Anti-VEGF antibodies
05/26/2005US20050112122 Generation of hematopoietic chimerism and induction of central tolerance
05/26/2005US20050112121 Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
05/26/2005US20050112120 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
05/26/2005US20050112119 Antibodies which bind human CXCR3
05/26/2005US20050112118 Compositions and methods for treating inflammatory disorders
05/26/2005US20050112117 Molecules and methods for inhibiting shedding of KIM-1
05/26/2005US20050112102 Viral proteins which stimulating immunology response
05/26/2005US20050112099 Nucleic acids encoding polypeptides; gene expression vectors; immunotherapy
05/26/2005US20050112091 Osteoporosis mixture of bone forming agents and nonabsorbent
05/26/2005US20050112090 Enhanced apoptosisinduced by tumor necrosis factor; administering to cell a polypeptide that gene expresses antagonist to tumor necrosis factor; anticancer agents; autoimmune diseases
05/26/2005US20050112062 Anti-idiotypic vascular endothelial growth factor antibodies and their use as medicaments
05/26/2005US20050112060 Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
05/26/2005CA2812856A1 Interleukin-10 antibodies
05/26/2005CA2805859A1 Il-18 binding proteins
05/26/2005CA2546323A1 Anti-idiotype antibodies of the human monoclonal antibody sc-1, and their production and use
05/26/2005CA2546077A1 Vaccine and method for treatment of neurodegenerative diseases
05/26/2005CA2545841A1 Use of lipopeptides for activating t lymphocytes through the skin
05/26/2005CA2545756A1 Antibodies against secretoryleukocyte protease inhibitor
05/26/2005CA2545718A1 Methods of using gelsolin to treat or prevent bacterial sepsis
05/26/2005CA2545603A1 Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
05/26/2005CA2545423A1 Combinations for the treatment of proliferative diseases
05/26/2005CA2545325A1 Compositions for reducing bacterial carriage and cns invasion and methods of using same
05/26/2005CA2545276A1 Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
05/26/2005CA2545187A1 Vegf receptor antagonists
05/26/2005CA2545183A1 Custom vectors for treating and preventing pancreatic cancer
05/26/2005CA2545164A1 Recombinant vectors expressing mucin and carcinoembryoinic antigen
05/26/2005CA2545152A1 Compositions and methods of treating neurological diseases
05/26/2005CA2544598A1 Antibodies to cd44 glycoforms and uses thereof
05/26/2005CA2544506A1 Use of strain of lactobacillus and byproducts thereof for inhibiting formation of blood vessels
05/26/2005CA2544483A1 Soluble tcr fusion molecules and methods of use
05/26/2005CA2543926A1 Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
05/26/2005CA2543920A1 Il-18 binding proteins
1 ... 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 ... 1823